The mechanisms underlying the progression of noninvasive serous borderline ovarian tumors (SBOT) to low-grade invasive carcinomas are poorly understood. We recently showed that inhibition of p53 induces SBOT invasion by activating the PI3K/Akt pathway and transcriptionally repressing E-cadherin. In human cancers, aberrant DNA methylation is a common phenomenon, and it is thought to be involved in the progression from noninvasive to invasive ovarian carcinomas. In this study, we tested the hypothesis that inhibition of p53 downregulates E-cadherin by regulating the methylation of its promoter in SBOT cells. Here, we show that DNA methyltransferase-1 (DNMT1), but not DNMT3a or DNMT3b, was increased in SV40 LT-infected SBOT4 cells, SBOT4-LT and the low-grade invasive serous ovarian carcinomaderived cell line MPSC1. Treatment with 5-Aza-dC, a DNMT1 inhibitor, restored E-cadherin promoter methylation and expression, and inhibited cell invasion in both invasive SBOT4-LT and MPSC1 cells. Moreover, knockdown of endogenous p53 using siRNA in SBOT3.1 cells induced DNMT1 expression and led to an increase in E-cadherin promoter methylation. Additionally, activation of the PI3K/Akt pathway is required for p53 inhibitioninduced DNMT1 expression. The increase in DNMT1 was associated with the inhibition of p53-induced downregulation of E-cadherin and cell invasion. Our findings show an important role for p53 in the progression of SBOT to an invasive carcinoma, and suggest that downregulation of E-cadherin by DNMT1-mediated promoter methylation contributes to this process.
Introduction
Progression of the transition from benign tumors to metastatic tumors is characterized by the acquisition of the ability to overcome cell-cell adhesion and invade surrounding tissue. E-cadherin is localized to the surface of epithelial cells in regions of cell-cell contacts known as adherens junctions, and it maintains cell polarity and normal epithelial structure (Pecina-Slaus, 2003; Cavallaro and Christofori, 2004 ). An early event of epithelial ovarian carcinogenesis is characterized by abnormal epithelial differentiation; in contrast to most epithelial cancers where downregulation of E-cadherin correlates with tumor progression, primary differentiated ovarian cancers express abundant E-cadherin. Although during the progression of cancer complete loss of E-cadherin expression is uncommon, reduced E-cadherin staining is often detected in late-stage ovarian cancer and in ascite-derived tumor cells (Hudson et al., 2008) . Repression of E-cadherin expression and mutations in the E-cadherin gene are prevalent in many epithelial cancers (Christofori and Semb, 1999) . Because mutations of the E-cadherin gene are very rare in ovarian carcinoma (Risinger et al., 1994) , alterations in E-cadherin expression that are associated with disease progression may be attributed to two mechanisms: downregulation of transcription by inhibitory transcription factors and hypermethylation of the promoter (Van Aken et al., 2001) .
DNA methylation is an epigenetic event in which a methyl group is added to the fifth carbon position of a cytosine residue that mostly occurs in CpG sites (Bird, 1980) . To date, three known classes of catalytically active DNA methyltransferases (DNMTs), DNMT1, DNMT3a and DNMT3b, have been cloned and characterized (Bestor, 2000) . DNMT1 is essential for maintaining DNA methylation patterns in proliferating cells (Leonhardt et al., 1992) . DNMT3a and DNMT3b are required for de novo methylation during embryonic development (Okano et al., 1999) . In human cancers, aberrant DNA methylation is one of the most consistent epigenetic mechanisms that regulate gene expression (Jones and Baylin, 2002) . The E-cadherin 5 0 transcriptional start site contains a dense CpG island. In different human cancers, downregulation of E-cadherin is linked to aberrant methylation of this CpG island (Yoshiura et al., 1995; Graff et al., 1997) . Inhibition of DNMT1 using small interfering RNA (siRNA) or the DNMT inhibitor 5-Aza-2 0 -deoxycytidine (5-Aza-dC) is sufficient to reverse promoter methylation in many tumor-suppressor genes, including E-cadherin (Graff et al., 1995; Fan et al., 2007) , and constitutive expression of DNMT1 is sufficient to induce tumorigenic transformation (Wu et al., 1993) .
Serous borderline ovarian tumors (SBOT) are noninvasive neoplasms that are considered to be distinct entities and give rise to invasive low-grade serous carcinomas (LGCs), which have a relatively poor prognosis (Gershenson et al., 1998; Vergara et al., 2010) . Mutation of p53 is the most common genetic alteration in highgrade invasive ovarian carcinomas, whereas it is rare in low-grade invasive carcinomas and borderline tumors (Schuijer and Berns, 2003; Singer et al., 2005) . Recently, we have shown that inhibition of p53 induces invasiveness in SBOT cells by downregulating E-cadherin expression. Downregulation of E-cadherin is mediated by increases in phosphatidylinositol-3-kinase (PI3K)/ Akt signaling and expression of transcriptional repressors (Cheng et al., 2011) . Deletion of p53 increases DNMT1 mRNA and protein levels, suggesting relief from p53-mediated DNMT1 repression (Peterson et al., 2003) . We therefore asked whether p53 is involved in the regulation of DNMT1 expression in SBOT cells and whether DNMT1-mediated epigenetic repression of E-cadherin may contribute to the transition from noninvasive borderline to invasive ovarian carcinomas.
Results

DNMT1 expression is increased in SV40 large T-antigen (LT)-infected SBOT cells
To investigate the effect that p53 has on DNMT1 expression in SBOT cells, we first examined DNMT1 expression in SV40 LT-infected SBOT cells, SBOT4-LT, which we generated recently (Cheng et al., 2011) . Reverse transcription-quantitative real-time PCR (RT-qPCR) results showed that DNMT1 mRNA levels were increased in SBOT4-LT cells compared with that in parental SBOT4 cells, whereas DNMT3a and DNMT3b levels did not vary significantly (Figure 1a) . Consistent with mRNA levels, DNMT1 protein levels also increased in SBOT4-LT cells, as determined by western blotting (Figure 1b) .
5-Aza-dC restores E-cadherin expression and decreases cell invasion in SBOT4-LT and MPSC1 cells Recently, we showed that inhibition of p53 caused E-cadherin to be downregulated in SBOT4-LT cells and in MPSC1 (invasive LGC cells) (Cheng et al., 2011) . RT-qPCR results showed that DNMT1 mRNA levels were higher in SBOT4-LT and MPSC1 cells compared with that in the spontaneously immortalized permanent cell line SBOT3.1. Consistent with mRNA levels, DNMT1 protein levels were also higher, as determined by western blotting (Figure 2a ). Therefore, we tested the possibility that E-cadherin promoter inactivation occurred through inhibition of p53-induced hypermethylation. E-cadherin mRNA and protein levels were examined after treating cells with the DNMT1 inhibitor 5-Aza-2 0 -deoxycytidine (5-Aza-dC). As shown in Figure 2b , 5-Aza-dC restored E-cadherin mRNA levels in a dose-dependent manner in both SBOT-4LT and MPSC1 cells. Consistent with this result, E-cadherin protein levels also increased in cells treated with 5-AzadC ( Figure 2c ). Additionally, methylation-specific PCR analysis showed that CpG island 1 from the E-cadherin promoter is methylated in SBOT4-LT and MPSC1 cells, and that this methylation was abolished by treatment with 5-Aza-dC (Figure 2d) . Because E-cadherin is an important invasion repressor in SBOT cells, we examined whether restoration of E-cadherin levels after treatment with 5-Aza-dC regulates cell invasion. As shown by the invasion assay, SBOT4-LT and MPSC1 cells were invasive, and their invasiveness was significantly inhibited by treatment with 5-Aza-dC (Figure 2e ). In addition, only high concentrations (20 mM) of 5-Aza-dC slightly inhibited SBOT4-LT and MPSC1 cell proliferation, as determined by counting cells using trypan blue (Supplementary Figure 1) . E-cadherin promoter methylation is mediated by DNMT1 in SBOT4-LT and MPSC1 cells To further confirm that the promoter methylation of E-cadherin is mediated by DNMT1, DNMT1 siRNA was used to knockdown the endogenous expression of DNMT1 in SBOT4-LT and MPSC1 cells. As shown in Figure 3a , the DNMT1 mRNA level was decreased in a time-dependent manner after treatment with DNMT1 siRNA. Conversely, the mRNA level of E-cadherin was increased by treatment with DNMT1 siRNA. Western blot showed similar results for the protein level (Figure 3b ). Additionally, DNMT1 siRNA abolished E-cadherin promoter methylation (Figure 3c) . Moreover, the invasiveness of SBOT4-LT and MPSC1 cells were significantly inhibited by DNMT1 siRNA treatment, which was reversed in combination with E-cadherin siRNA (Figure 3d ). These results indicated that DNMT1 siRNA-inhibited SBOT4-LT and MPSC1 cell invasion was mediated by restoring the expression of E-cadherin.
Inhibition of p53, but not Rb, increases DNMT1 in SBOT cells It is well known that SV40 LT inhibits both p53 and Rb. To further discriminate between the effects of p53 and Rb on DNMT1 expression, we knocked down endogenous p53 or Rb and examined the expression of DNMT1 in SBOT3.1 cells. As shown in Figure 4a , p53 and Rb siRNA significantly knocked down p53 and Rb mRNA levels, respectively. Interestingly, only p53 siRNA increased DNMT1 mRNA levels, whereas DNMT1 mRNA levels were not affected by Rb siRNA treatment. DNMT3a and DNMT3b mRNA levels were not changed after treatment with either p53 or Rb siRNA in SBOT3.1 cells (Figure 4b ). Western blot showed that p53 inhibition led to an increase in DNMT1 protein levels ( Figure 4c ). To further confirm that DNMT1 expression induced through inhibition of p53 contributes to methylation of the E-cadherin promoter, SBOT3.1 cells were treated with p53 siRNA and methylation of the E-cadherin promoter was examined using methylation-specific PCR. As shown in Figure 4d , E-cadherin promoter methylation increased following p53 siRNA treatment.
The PI3K/Akt pathway mediates the upregulation of DNMT1 through p53 inhibition We have shown that p53 inhibition increases the expression of the catalytic subunit of PI3K (PIK3CA, p110a) and Akt activation (Cheng et al., 2011) . Therefore, we investigated whether the PI3K/Akt pathway is involved in the p53-mediated regulation of DNMT1 expression. SBOT4-LT and MPSC1 cells were transfected with PIK3CA siRNA and Myc-tagged dominant-negative Akt (DN-Akt), and DNMT1 mRNA and protein levels were examined. Treatment with PIK3CA siRNA significantly knocked down PIK3CA mRNA levels (Supplementary Figure 2) . DNMT1 mRNA and protein levels were downregulated in SBOT4-LT and MPSC1 cells treated with the PIK3CA siRNA ( Figure 5a ). In addition, cells transfected with DN-Akt also had lower DNMT1 mRNA and protein levels ( Figure 5b ). When SBOT3.1 cells were treated with a combination of PIK3CA siRNA and p53 siRNA, the p53 siRNAmediated upregulation of DNMT1 mRNA and protein levels was diminished ( Figure 5c ).
DNMT1-mediated promoter methylation is required for inhibition of the p53-mediated downregulation of E-cadherin
To further investigate whether DNMT1 is required in the p53-mediated downregulation of E-cadherin, SBOT3.1 cells were treated with p53 siRNA, DNMT1 siRNA or both, and methylation of the E-cadherin promoter was examined. Methylation-specific PCR showed that p53 siRNA caused an increase in promoter methylation, whereas DNMT1 siRNA caused a decrease in promoter methylation compared with that in control cells. Interestingly, the increase in promoter methylation caused by p53 siRNA was abolished by co-treatment with DNMT1 siRNA (Figure 6a ). p53 siRNA caused a decrease in Ecadherin protein levels, and this decrease was diminished by co-treatment with DNMT1 siRNA, as determined by western blotting (Figure 6b ). However, in cells treated with DNMT1 siRNA, there were no significant increases in E-cadherin protein levels. Moreover, cells transfected with p53 siRNA in combination with DNMT1 siRNA diminished p53 siRNA-induced cell invasion, as determined using an invasion assay (Figure 6c ). Taken together, these results indicate that inhibition of p53-induced downregulation of E-cadherin is partly mediated by promoter methylation by DNMT1 and is associated with cell invasion in SBOT cells.
Discussion
In ovarian cancer, aberrant methylation of multiple CpG islands is a frequent event compared with normal ovarian surface epithelium, and inactivation of several genes, including tumor-suppressor genes, by aberrant methylation of CpG islands has been documented (Balch et al., 2009; Asadollahi et al., 2010) . Recently, we showed that inhibition of p53 increases SBOT cell invasion by increasing the level of the transcriptional repressors Slug and Twist, leading to the downregulation of E-cadherin (Cheng et al., 2011) . However, it is unknown whether changes in promoter methylation are involved in the inhibition of p53-induced downregulation of E-cadherin. In the present study, we found that DNMT1 levels, but not DNMT3a or DNMT3b levels, increased in SBOT cells after p53 was inhibited. Activation of the PI3K/Akt pathway is required for p53 inhibition-induced DNMT1 expression. Furthermore, the increase in DNMT1 contributes to E-cadherin promoter methylation, leading to downregulation of E-cadherin and SBOT cell invasion. Previously, we have shown that p53 binds directly to the PIK3CA promoter and inhibits its activity in ovarian cancer cells (Astanehe et al., 2008) . In addition, p53 inhibition increases the expression of the PIK3CA and Akt activation in SBOT cells (Cheng et al., 2011) . Taken together, our results indicate that p53 acts as a tumor suppressor in the progression from SBOT to invasive ovarian carcinoma by regulating E-cadherin expression through PI3K/Akt-mediated transcriptional and epigenetic machineries (Figure 7) .
Previous studies have compared epigenetic aberrations in benign, borderline and malignant invasive ovarian tumors. The results from these studies showed that borderline tumors have a methylation profile that is in between that of benign and malignant invasive tumors. In addition, data on aberrant epigenetic alterations suggest that some invasive ovarian cancers may originate through an accumulation of methylation events at specific genes in noninvasive precursor lesions (Cheng et al., 1997; Makarla et al., 2005; Tam et al., 2007) . Interestingly, these studies also support the dualistic model for ovarian carcinogenesis (Shih Ie and Kurman, 2004) . However, the detailed mechanism underlying gene methylation and ovarian cancer progression requires further investigation.
Mutation of p53 is the most common genetic alteration in high-grade invasive ovarian carcinomas, whereas it is rare in low-grade invasive carcinomas and borderline tumors (Singer et al., 2005) . We recently showed that inhibition of p53 activity, either by SV40 LT or p53 siRNA, increased the invasiveness of SBOT cells (Cheng et al., 2011) . Additionally, a microarray study showed that expression profiles from low-grade invasive carcinomas lack the enhanced p53 expression and signaling activity observed in SBOT cells (Bonome et al., 2005) . These results indicate that the progression from SBOT to low-grade invasive carcinoma involves Loss of p53 increases DNMT1 and E-cadherin promoter methylation J-C Cheng et al attenuation of p53 signaling. p53 is a very important tumor-suppressor gene and is reported to be abnormal in most human cancers (Vogelstein et al., 2000) . p53-binding sites have been identified in the 5 0 -flanking region and exon-1 of the human DNMT1 genomic locus (Peterson et al., 2003) . In addition, several p53-binding sites are also found in the 5 0 region of the mouse DNMT1 locus (Peterson et al., 2003) . Deletion of p53 in human colon carcinoma cells and primary mouse astrocytes results in an increase in DNMT1 mRNA and protein, suggesting that p53 mediates the transcriptional repression of this gene (Peterson et al., 2003) . Recently, it was shown that activation of the PI3K/Akt pathway increases DNMT1 protein levels (Sun et al., 2007) . In the present study, we found that inhibition of p53 increases DNMT1 expression. In addition, inhibition of the PI3K/Akt pathway diminished the upregulation of DNMT1 when p53 is inhibited. However, we did Loss of p53 increases DNMT1 and E-cadherin promoter methylation J-C Cheng et al not show direct binding of p53 to the DNMT1 promoter in SBOT cells. Thus, whether expression of DNMT1 is regulated by direct binding of p53 to the DNMT1 promoter or by p53-mediated upregulation of PI3K/Akt signaling will need further investigation. The defining characteristic of epithelial-mesenchymal transition is a downregulation in E-cadherin expression (Lee et al., 2006) . The PI3K/Akt pathway is important in ovarian carcinogenesis and is implicated in the regulation of cell migration, invasion and epithelialmesenchymal transition (Fresno Vara et al., 2004; Sheng et al., 2009) . It has been shown that the PI3K/Akt pathway can interact with other pathways of epithelialmesenchymal transition such as tyrosine kinases, Wnt/ b-catenin, RAS, Notch and integrin-linked kinase signaling (Larue and Bellacosa, 2005) . Squamous cell carcinoma cell lines show constitutive activation of Akt, which downregulates the expression of E-cadherin and promotes tumorigenicity and invasiveness (Grille et al., 2003) . Such findings indicate that activation of the PI3K/Akt axis coupled with downregulation of E-cadherin expression may be important in promoting tumorigenesis.
DNMT1 is the most extensively studied and the most abundant DNMT; it is thought to be responsible for replicating methylation patterns after DNA synthesis (Robertson et al., 1999) . DNMT1 knockouts are resistant to colorectal tumorigenesis, and antisense knockdowns of DNMT1 reverse tumorigenesis in vitro and in vivo (Laird et al., 1995; MacLeod and Szyf, 1995; Ramchandani et al., 1997) . In ovarian cancer, differential DNMT gene expression has been examined, and it has been suggested that alterations in DNMT expression might contribute to the CpG island methylation phenotype (Ahluwalia et al., 2001) . RNA interference-mediated downregulation of DNMT1 protein expression restores the expression of some inactive genes, such as RASSF1A and HIN-1, due to a decrease in the methylation levels of these genes in an ovarian cancer cell line (Leu et al., 2003) . We found that the increase in DNMT1 expression caused by p53 inhibition leads to the downregulation of E-cadherin expression, and contributes to the invasiveness of SBOT cells. Our results may also explain the higher level of DNMT1 in high-grade serous ovarian cancer cells, which frequently possesses mutant p53 when compared with that in normal ovarian surface epithelial cells (Ahluwalia et al., 2001) . Taken together, these results indicate that DNMT1 is required to maintain the aberrant methylation in cancer cells, and that the DNMT1-regulated methylation of these sites is required for transcriptional silencing of tumor-suppressor genes in human cancer.
Ovarian cancer cells with low E-cadherin expression are more invasive (Veatch et al., 1994) , and absence of E-cadherin expression in ovarian cancer predicts poor patient survival compared with that in ovarian tumors that express E-cadherin (Darai et al., 1997) . Several studies have shown that DNMT1 is necessary to maintain the methylation of CpG islands in the E-cadherin promoter Shieh et al., 2005; Fan et al., 2007; Benton et al., 2009) . However, recent studies in endometrial epithelial carcinoma and choriocarcinoma cell lines have shown that the siRNAmediated downregulation of the individual DNMT genes did not cause an increase in E-cadherin expression; however, concurrent knockdowns of DNMT3a and DNMT3b induced E-cadherin expression. Furthermore, E-cadherin expression significantly increased after concomitant knockdown of DNMT1, 3a and 3b (Rahnama et al., 2006 (Rahnama et al., , 2009 ). Here we show that inhibition of p53 leads to an increase in DNMT1 expression and does not alter the expression of DNMT3a or DNMT3b in SBOT cells. These results suggest that epigenetic regulation of E-cadherin by DNMTs might be tissue-specific.
In summary, the results from this study indicate that inhibition of p53 downregulates E-cadherin by Loss of p53 increases DNMT1 and E-cadherin promoter methylation J-C Cheng et al increasing DNMT1 expression and the subsequent E-cadherin promoter methylation in SBOT cells. This function suggests that p53 acts as an ovarian epithelial tumor suppressor by regulating gene methylation in the progression from SBOT to invasive ovarian carcinoma.
Materials and methods
Cell culture
The SBOT3.1 and SV40 LT-infected SBOT4-LT cells were grown in a 1:1 (v/v) mixture of M199/MCDB105 media (Sigma, Oakville, ON, USA) supplemented with 10% fetal bovine serum (Hyclone Laboratories Inc., Logan, UT, USA). The MPSC1 cell line, which was established from an LGC (provided by Dr Ie-Ming Shih, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA), was maintained in RPMI 1640 (Invitrogen, Burlington, ON, USA) supplemented with 10% fetal bovine serum (Pohl et al., 2005) . Cultures were maintained at 37 1C in a humidified atmosphere of 5% CO 2 in air.
Western blots
Cells were lysed and protein concentrations were analyzed with a protein assay kit using BSA standards according to the Upon p53 loss during progression from noninvasive SBOT to the invasive phenotype, PIK3CA level is increased and subsequently enhances the activation of Akt. The increased PI3K/Akt signaling leads to E-cadherin downregulation by two pathways: (A) it can increase the E-cadherin transcriptional repressors Slug and Twist, which downregulate E-cadherin expression by suppressing transcription and (B) it can increase DNMT1 expression, which downregulates E-cadherin expression by increasing its promoter methylation. Once the expression of E-cadherin has been downregulated, SBOT cells become invasive. DNMT1, DNA methyltransferase-1; PI3K, phosphatidylinositol-3-kinase; SBOT, serous borderline ovarian tumors.
Loss of p53 increases DNMT1 and E-cadherin promoter methylation J-C Cheng et al manufacturer's instructions (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of cell lysates were separated by sodium dodecyl sulfate-PAGE and transferred to polyvinylidene difluoride membranes. After blocking with TBS containing 5% non-fat dry milk, the membranes were incubated overnight at 4 1C with anti-E-cadherin (BD Biosciences, Mississauga, ON, Canada), anti-DNMT1 (Abnova, Taipei, Taiwan) and anti-p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies, followed by incubation with a horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were detected using an enhanced chemiluminescence kit. The membrane was stripped with stripping buffer and re-probed with an anti-b-actin antibody as loading control.
Reverse transcription-qPCR Total RNA was extracted using the TRIzol reagent (Invitrogen) according to the manufacturer's instructions. 0 -GAGTCA ACGGATTTGGTCGT-3 0 and 5 0 -GACAAGCTTCCCGTTC TCAG-3 0 . RT-qPCR was performed using the ABI Prism 7000 Sequence Detection System equipped with a 96-well optical reaction plate. All RT-qPCR experiments were run in triplicate and a mean value was used to determine mRNA levels. Relative quantification of mRNA levels was performed using the comparative C t method with GAPDH as the reference gene and the formula 2 ÀDDC t .
Methylation-specific PCR (MSP)
Detection of E-cadherin promoter methylation was performed as previously described by Herman et al. (1996) . Briefly, genomic DNA was extracted from cells and unmethylated cytosine bases were converted to uracil using the Imprint DNA Modification kit (Sigma). The following primers were used for the amplification of a 116-bp fragment corresponding to the E-cadherin methylated promoter region: forward primer 5 0 -TTAGGTTAGAGGGTTATCGCGT-3 0 and reverse primer, 5 0 -TAACTAAAAATTCACCTACCGAC-3 0 . The following primers were used for the amplification of a 97-bp fragment corresponding to the unmethylated promoter region: forward primer, 5 0 -TAATTTTAGGTTAGAGGGTTATTGT-3 0 and reverse primer, 5 0 -CACAACCAATCAACAACACA-3 0 . Methylation-specific PCR was performed using the following cycling conditions: denaturation at 95 1C for 5 min, followed by 40 cycles at 95 1C for 30 s, 57 1C for 1 min and 72 1C for 1 min, with a final extension at 72 1C for 5 min. The methylation-specific PCR bands were detected by electrophoresis in a 2% agarose gel stained with ethidium bromide.
Invasion assay
The invasion assay was performed using Boyden chambers (Woo et al., 2007) . Filters (8-mm pore size, 24 wells; BD Biosciences) were coated with 1 mg/ml growth-factor-reduced Matrigel (BD Biosciences). Cells in M199/MCDB105 media supplemented with 0.1% fetal bovine serum were incubated for 48 h against a gradient of 10% fetal bovine serum. Cells that penetrated the membrane were fixed with cold methanol and stained with Hoechst 33258, and the number of nuclei stained with Hoechst 33258 was counted using the Northern Eclipse 6.0 software from Empix Imaging (Mississauga, ON, Canada). Each individual experiment consisted of triplicate inserts, and five microscopic fields were counted per insert.
siRNA and transfection
To inactivate p53, E-cadherin and DNMT1, cells were transfected with p53, E-cadherin and DNMT1 siRNA (Dharmacon Research Inc., Lafayette, CO, USA) using Lipofectamine RNAiMAX (Invitrogen). The non-targeting siRNA (Dharmacon) was used as a transfection control. Myctagged DN-Akt (Upstate, Billerica, MA, USA) was transfected into cells using Lipofectamine 2000.
Statistical analysis
Results are presented as the mean ± s.e.m. of at least three independent experiments. Statistical evaluation was conducted using t-test for paired data. Multiple comparisons were analyzed first by one-way analysis of variance, followed by Tukey's multiple comparison tests. A significant difference was defined as Po0.05.
